JP5896589B2 - 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス - Google Patents
疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス Download PDFInfo
- Publication number
- JP5896589B2 JP5896589B2 JP2009531382A JP2009531382A JP5896589B2 JP 5896589 B2 JP5896589 B2 JP 5896589B2 JP 2009531382 A JP2009531382 A JP 2009531382A JP 2009531382 A JP2009531382 A JP 2009531382A JP 5896589 B2 JP5896589 B2 JP 5896589B2
- Authority
- JP
- Japan
- Prior art keywords
- symptoms
- children
- group
- disease
- term
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 62
- 201000010099 disease Diseases 0.000 title description 61
- 239000006041 probiotic Substances 0.000 title description 39
- 235000018291 probiotics Nutrition 0.000 title description 39
- 208000024891 symptom Diseases 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 26
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 24
- 206010037660 Pyrexia Diseases 0.000 claims description 21
- 206010022004 Influenza like illness Diseases 0.000 claims description 18
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 17
- 235000015872 dietary supplement Nutrition 0.000 claims description 17
- 239000003242 anti bacterial agent Substances 0.000 claims description 15
- 206010011224 Cough Diseases 0.000 claims description 14
- 208000036071 Rhinorrhea Diseases 0.000 claims description 14
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 description 43
- 230000000529 probiotic effect Effects 0.000 description 29
- 239000000902 placebo Substances 0.000 description 28
- 229940068196 placebo Drugs 0.000 description 28
- 239000000047 product Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 244000005700 microbiome Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 235000013336 milk Nutrition 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 10
- 206010028813 Nausea Diseases 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 230000008693 nausea Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 208000023409 throat pain Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023848 Laryngeal pain Diseases 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
定義
℃(摂氏 (degrees Centigrade))、H2O(水 (water))、gm(グラム (grams))、μg及びug(マイクログラム (micrograms))、mg(ミリグラム (milligrams))、ng(ナノグラム (nanograms))、μl及びul(マイクロリットル (microliters))、ml(ミリリットル (milliliters))、mm(ミリメートル (millimeters))、nm(ナノメートル (nanometers))、μm及びum(マイクロメートル (micrometer))、M(モル (molar))、mM(ミリモル (millimolar))、μM及びuM(マイクロモル (micromolar))、U(ユニット (units))、sec(秒 (seconds))、min(s)(分 (minute/minutes))、hr(s)(時間 (hour/hours))、sd及びSD(標準偏差 (standard deviation))、PBS(リン酸緩衝生理食塩水(phosphate buffered saline [150mM NaCl、 10mM sodium phosphate buffer、 pH7.2])、w/v(質量/体積 (weight to volume))、v/v(体積/体積 (volume to volume))、 CFU(コロニー形成単位 (colony forming units))及びNCFM(ノースカロライナ食品微生物学部門 (North Carolina Food Microbiology Department))、Becton Dickinson(ベクトン ディッキンソン (Becton Dickinson Diagnostic Systems, Sparks, MD))、Difco(ディフコ (Difco Laboratories, Detroit, MI))、GIBCO BRL又はGibco BRL(ギブコ (Life Technologies, Inc., Gaithersburg, MD))、ATCC(アメリカ培養細胞系統保存機関 (American Type Culture Collection, Manassas, VA))。
A.試験計画
B.デイケアセンターの場所の妥当性
C.出席用紙の書類
D.結果測定
E.統計分析
F.結果
Claims (13)
- 小児における、インフルエンザ様症状のうち発熱、咳、及び鼻水からなる群から選択される少なくともひとつの症状の治療又は予防用組成物を調製するためにラクトバチルス・アシドフィルス(L. acidophilus)NCFM(PTA−4797)及びビフィドバクテリウム・ラクティス(B. lactis)Bi−07(PTA−4802)を使用する方法。
- 前記小児が未就学児であることを特徴とする、請求項1に記載の方法。
- 前記組成物が秋又は冬の月の間に投与されることを特徴とする、請求項1又は2に記載の方法。
- 前記組成物が口から投与されることを特徴とする、請求項1から3のいずれか一項に記載の方法。
- 前記組成物が栄養補助食品中に添加されることを特徴とする、請求項1から4のいずれか一項に記載の方法。
- 前記組成物により前記小児における前記インフルエンザ様症状の治療するための抗菌剤の投与の必要性が減少することを特徴とする、請求項1から5のいずれか一項に記載の方法。
- 小児における、インフルエンザ様症状のうち発熱、咳、及び鼻水からなる群から選択される少なくともひとつの症状の発現を防止するための予防用組成物を調製するためにラクトバチルス・アシドフィルス(L. acidophilus)NCFM(PTA−4797)及びビフィドバクテリウム・ラクティス(B. lactis)Bi−07(PTA−4802)を使用する方法。
- 小児における、インフルエンザ様症状のうち発熱、咳、及び鼻水からなる群から選択される少なくともひとつの症状の進行を防止するための治療用組成物を調製するためにラクトバチルス・アシドフィルス(L. acidophilus)NCFM(PTA−4797)及びビフィドバクテリウム・ラクティス(B. lactis)Bi−07(PTA−4802)を使用する方法。
- 前記小児が未就学児であることを特徴とする、請求項7又は8に記載の方法。
- 前記組成物が秋又は冬の月の間に投与されることを特徴とする、請求項7から9のいずれか一項に記載の方法。
- 前記組成物が口から投与されることを特徴とする、請求項7から10のいずれか一項に記載の方法。
- 前記組成物が栄養補助食品中に添加されることを特徴とする、請求項7から11のいずれか一項に記載の方法。
- 前記組成物により前記小児における前記インフルエンザ様症状の治療するための抗菌剤の投与の必要性が減少することを特徴とする、請求項7から12のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84866206P | 2006-10-02 | 2006-10-02 | |
US60/848,662 | 2006-10-02 | ||
PCT/US2007/020033 WO2008042101A2 (en) | 2006-10-02 | 2007-09-14 | Probiotics for use in reducing the incidence and duration of illness |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013251839A Division JP2014058558A (ja) | 2006-10-02 | 2013-12-05 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010505824A JP2010505824A (ja) | 2010-02-25 |
JP2010505824A5 JP2010505824A5 (ja) | 2010-04-22 |
JP5896589B2 true JP5896589B2 (ja) | 2016-03-30 |
Family
ID=39268947
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009531382A Active JP5896589B2 (ja) | 2006-10-02 | 2007-09-14 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
JP2013251839A Pending JP2014058558A (ja) | 2006-10-02 | 2013-12-05 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
JP2016014585A Pending JP2016128478A (ja) | 2006-10-02 | 2016-01-28 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013251839A Pending JP2014058558A (ja) | 2006-10-02 | 2013-12-05 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
JP2016014585A Pending JP2016128478A (ja) | 2006-10-02 | 2016-01-28 | 疾病の罹患率及び持続期間を減少する使用のためのプロバイオティクス |
Country Status (12)
Country | Link |
---|---|
US (5) | US20100040579A1 (ja) |
EP (2) | EP2068899B1 (ja) |
JP (3) | JP5896589B2 (ja) |
KR (2) | KR101485200B1 (ja) |
CN (1) | CN101528244B (ja) |
AU (1) | AU2007302715B2 (ja) |
BR (1) | BRPI0719787A2 (ja) |
DK (2) | DK2839836T3 (ja) |
ES (2) | ES2650375T3 (ja) |
MX (1) | MX2009003260A (ja) |
PL (2) | PL2068899T3 (ja) |
WO (1) | WO2008042101A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2835860B1 (en) | 2009-12-02 | 2018-03-07 | KMW Inc. | Device selection structure |
JP5885287B2 (ja) * | 2010-09-02 | 2016-03-15 | アサヒカルピスウェルネス株式会社 | インフルエンザの予防および/または治療剤 |
CN105288616B (zh) * | 2010-10-15 | 2018-10-19 | 科.汉森有限公司 | 免疫佐剂 |
EP2455093A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic bacteria and prevention or treatment of infections in children |
EP2455092A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
EP3068404B1 (en) | 2013-11-15 | 2021-01-06 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk |
CN104886255B (zh) * | 2014-03-07 | 2018-11-27 | 内蒙古伊利实业集团股份有限公司 | 具有缓解咽喉部炎症功效的益生菌食品组合物及食品 |
US11229658B2 (en) | 2015-03-05 | 2022-01-25 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
US11638726B2 (en) | 2019-09-25 | 2023-05-02 | Tall Goods Llc | Methods for producing probiotics fortified avian eggs and egg products and formulations thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4007A (en) * | 1845-04-22 | Improvement in separating tannin and coloring-matter in quercitron-bark | ||
WO1998023727A1 (en) * | 1996-11-29 | 1998-06-04 | Bio K + International Inc. | Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof |
JP4212838B2 (ja) * | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
OA13142A (en) | 2002-10-11 | 2006-12-13 | Wyeth Corp | Nutritional formulations containing synbiotic substances. |
US20090257993A1 (en) * | 2003-12-17 | 2009-10-15 | M Rabet Laura | Lactic Acid Producing Bacteria and Lung Function |
DE102004026706A1 (de) * | 2004-05-28 | 2005-12-15 | Merck Patent Gmbh | Orale Darreichungsform enthaltend probiotische Bakterien |
CA2470090A1 (fr) * | 2004-06-18 | 2005-12-18 | Bio-K Plus International Inc. | Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques |
US7862808B2 (en) † | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
ITMI20042189A1 (it) * | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
ES2348403T3 (es) * | 2005-02-15 | 2010-12-03 | Barry R. Goldin | Un alimento que contiene un probiotico y un beta-glucano aislado y metodos de uso del mismo. |
US20070020249A1 (en) * | 2005-04-29 | 2007-01-25 | Downs Bernard W | Compositions for prevention and treatement of symptoms of gastrointestinal distress |
PL1951273T3 (pl) | 2005-10-06 | 2014-07-31 | Probi Ab | Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych |
-
2007
- 2007-09-14 DK DK14186663.2T patent/DK2839836T3/en active
- 2007-09-14 MX MX2009003260A patent/MX2009003260A/es active IP Right Grant
- 2007-09-14 KR KR20097006213A patent/KR101485200B1/ko active IP Right Grant
- 2007-09-14 ES ES14186663.2T patent/ES2650375T3/es active Active
- 2007-09-14 ES ES07838266.0T patent/ES2547480T3/es active Active
- 2007-09-14 BR BRPI0719787-0A2A patent/BRPI0719787A2/pt not_active Application Discontinuation
- 2007-09-14 EP EP07838266.0A patent/EP2068899B1/en active Active
- 2007-09-14 PL PL07838266T patent/PL2068899T3/pl unknown
- 2007-09-14 KR KR1020137030884A patent/KR101474188B1/ko active IP Right Grant
- 2007-09-14 WO PCT/US2007/020033 patent/WO2008042101A2/en active Application Filing
- 2007-09-14 CN CN2007800366675A patent/CN101528244B/zh active Active
- 2007-09-14 US US12/441,660 patent/US20100040579A1/en not_active Abandoned
- 2007-09-14 DK DK07838266.0T patent/DK2068899T3/da active
- 2007-09-14 PL PL14186663T patent/PL2839836T3/pl unknown
- 2007-09-14 JP JP2009531382A patent/JP5896589B2/ja active Active
- 2007-09-14 AU AU2007302715A patent/AU2007302715B2/en active Active
- 2007-09-14 EP EP14186663.2A patent/EP2839836B2/en active Active
-
2013
- 2013-12-05 JP JP2013251839A patent/JP2014058558A/ja active Pending
-
2014
- 2014-08-14 US US14/460,350 patent/US20140356329A1/en not_active Abandoned
-
2016
- 2016-01-28 JP JP2016014585A patent/JP2016128478A/ja active Pending
-
2017
- 2017-02-16 US US15/434,376 patent/US20180000875A1/en not_active Abandoned
-
2020
- 2020-02-03 US US16/779,792 patent/US20200316145A1/en not_active Abandoned
-
2022
- 2022-09-15 US US17/945,293 patent/US20230256037A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR101474188B1 (ko) | 2014-12-17 |
EP2068899A2 (en) | 2009-06-17 |
BRPI0719787A2 (pt) | 2014-11-25 |
EP2839836A1 (en) | 2015-02-25 |
ES2547480T3 (es) | 2015-10-06 |
KR20140002069A (ko) | 2014-01-07 |
WO2008042101A3 (en) | 2009-04-09 |
EP2068899B1 (en) | 2015-07-01 |
DK2839836T3 (en) | 2017-12-04 |
MX2009003260A (es) | 2009-05-11 |
EP2839836B2 (en) | 2024-06-26 |
CN101528244B (zh) | 2012-01-11 |
US20100040579A1 (en) | 2010-02-18 |
US20140356329A1 (en) | 2014-12-04 |
PL2068899T3 (pl) | 2015-12-31 |
DK2068899T3 (da) | 2015-09-28 |
ES2650375T3 (es) | 2018-01-18 |
AU2007302715B2 (en) | 2013-01-31 |
US20200316145A1 (en) | 2020-10-08 |
AU2007302715A1 (en) | 2008-04-10 |
EP2839836B1 (en) | 2017-08-30 |
KR20090063222A (ko) | 2009-06-17 |
JP2016128478A (ja) | 2016-07-14 |
PL2839836T3 (pl) | 2018-02-28 |
WO2008042101A2 (en) | 2008-04-10 |
CN101528244A (zh) | 2009-09-09 |
KR101485200B1 (ko) | 2015-01-26 |
JP2010505824A (ja) | 2010-02-25 |
JP2014058558A (ja) | 2014-04-03 |
US20230256037A1 (en) | 2023-08-17 |
US20180000875A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230256037A1 (en) | Probiotics for use in reducing the incidence and duration of illness | |
Hojsak et al. | Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial | |
Guillemard et al. | Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial | |
Schlager et al. | Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization | |
Saavedra et al. | Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety | |
TWI374745B (en) | Use of a combination of bifidobacterium lactis bb-12 and lactobacillus rhamnosus gg for preventing or treating respiratory infections and acute otitis media in infants | |
Fujita et al. | Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: a multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population | |
ES2399775T3 (es) | Composiciones farmacéuticas que comprenden L. acidophilus y bifidobacterium lactis para el uso en el tratamiento de un trastorno intestinal funcional | |
CN107206034A (zh) | 包含双歧杆菌的免疫调节组合物 | |
Manzano et al. | Safety and tolerance of three probiotic strains in healthy infants: A multi-centre randomized, double-blind, placebo-controlled trial | |
Hubbard et al. | Synbiotic containing extensively hydrolyzed formula improves gastrointestinal and atopic symptom severity, growth, caregiver quality of life, and hospital‐related healthcare use in infants with cow's milk allergy | |
Banerjee et al. | Importance of probiotics in human health | |
AU2013201783B2 (en) | Probiotics for use in reducing the incidence and duration of illness | |
Nunes | Probiotics and enzymes in the gastrointestinal tract | |
US20190091270A1 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
Varshney | An analysis of probiotics | |
Kloster Smerud et al. | Effect of a probiotic milk product on gastrointestinal and respiratory infections in children attending day-care | |
Wu et al. | Bifidobacteria and Lactobacillus rhamnosus Affecting Respiratory Infections and Immune Function in Children | |
Ahmed et al. | The Effect of Oral Lactase Enzyme on Infantile Colic in The First 4 Months of Life: A Prospective Case Control Study | |
Read | The effect of Lactobacillus reuteri supplementation on anthropometric measurements, lung function and lung infections in a cystic fibrosis population in KwaZulu-Natal. | |
Mittal | EFFECT OF PROBIOTICS ON TEETHING PROBLEMS IN INFANTS/TODDLERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100303 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20121012 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131008 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131107 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131205 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140912 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140919 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20141107 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150126 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150219 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5896589 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |